Overview

Combination Chemotherapy as Induction Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

Status:
Completed
Trial end date:
2002-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy with docetaxel, gemcitabine, and cisplatin as induction therapy in treating patients with stage III non-small cell lung cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Cisplatin
Docetaxel
Gemcitabine